Teladoc Health (NYSE:TDOC) was upgraded by equities research analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report issued on Monday, Marketbeat Ratings reports. The brokerage presently has a $80.00 price target on the health services provider’s stock. Robert W. Baird’s price objective suggests a potential upside of 39.40% from the stock’s previous close. The analysts noted that the move was a valuation call.
Other equities research analysts have also recently issued reports about the company. raised their price target on Teladoc Health from $68.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, September 28th. Cantor Fitzgerald lifted their target price on Teladoc Health from $52.00 to $83.00 and gave the stock a “neutral” rating in a report on Friday, September 28th. They noted that the move was a valuation call. Citigroup reaffirmed a “buy” rating and issued a $95.00 target price on shares of Teladoc Health in a report on Friday, September 28th. Piper Jaffray Companies lifted their target price on Teladoc Health to $84.00 and gave the stock an “overweight” rating in a report on Friday, September 21st. Finally, KeyCorp lifted their target price on Teladoc Health from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Friday, September 28th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $82.14.
NYSE TDOC traded up $1.92 on Monday, hitting $57.39. 315,565 shares of the company traded hands, compared to its average volume of 1,379,525. The company has a market capitalization of $3.86 billion, a PE ratio of -34.78 and a beta of 1.21. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.99 and a current ratio of 8.99. Teladoc Health has a 52-week low of $30.88 and a 52-week high of $89.05.
Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Thursday, November 1st. The health services provider reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02. The business had revenue of $111.00 million for the quarter, compared to analysts’ expectations of $109.94 million. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The business’s quarterly revenue was up 61.6% on a year-over-year basis. During the same period last year, the firm earned ($0.55) earnings per share. On average, sell-side analysts forecast that Teladoc Health will post -1.48 EPS for the current year.
In related news, CEO Jason N. Gorevic sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 19th. The stock was sold at an average price of $49.55, for a total value of $1,486,500.00. Following the completion of the sale, the chief executive officer now owns 536,184 shares in the company, valued at $26,567,917.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam C. Vandervoort sold 5,549 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $67.18, for a total value of $372,781.82. Following the completion of the sale, the insider now owns 2,934 shares of the company’s stock, valued at approximately $197,106.12. The disclosure for this sale can be found here. Insiders have sold 208,683 shares of company stock valued at $12,872,473 in the last 90 days. Company insiders own 3.95% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Retirement Systems of Alabama raised its stake in Teladoc Health by 76.1% in the fourth quarter. Retirement Systems of Alabama now owns 70,800 shares of the health services provider’s stock worth $3,510,000 after buying an additional 30,600 shares in the last quarter. Vanguard Group Inc raised its stake in Teladoc Health by 26.9% in the third quarter. Vanguard Group Inc now owns 5,874,182 shares of the health services provider’s stock worth $507,236,000 after buying an additional 1,244,388 shares in the last quarter. Federated Investors Inc. PA bought a new position in Teladoc Health in the third quarter worth approximately $3,021,000. Marshall Wace North America L.P. raised its stake in Teladoc Health by 313.5% in the third quarter. Marshall Wace North America L.P. now owns 202,001 shares of the health services provider’s stock worth $17,443,000 after buying an additional 153,146 shares in the last quarter. Finally, Reynders McVeigh Capital Management LLC raised its stake in Teladoc Health by 2.8% in the third quarter. Reynders McVeigh Capital Management LLC now owns 145,529 shares of the health services provider’s stock worth $12,566,000 after buying an additional 3,930 shares in the last quarter.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
See Also: How to read a candlestick chart
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.